secwatch.observer — SEC 8-K summary
======================================

Issuer:     Design Therapeutics, Inc. (DSGN)
CIK:        0001807120
Form:       8-K
Filed at:   2023-08-25T23:59:59+00:00
Accession:  0001193125-23-221586
Event type: leadership
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Design Therapeutics CEO Siffert resigns; Chair Shah appointed CEO, receives stock options
--------------------------------------------------------------------------------

- João Siffert resigned as President/CEO/principal financial officer effective Aug 25, 2023; employee status ends Sept 1, 2023.
- Pratik Shah, Ph.D., Board Chair, appointed President, CEO and principal financial officer effective Aug 25, 2023; Simeon George named lead independent director.
- Siffert receives 12-month salary continuation, $230,220 prorated bonus, 12-month COBRA, extended option exercisability (6 months).
- Shah granted options: 1,050,000 shares time-vesting; 525,000 shares contingent on FA IND clearance; 525,000 shares contingent on FA Phase 2a start.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1807120/000119312523221586/0001193125-23-221586-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1807120/000119312523221586/d530547d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-221586

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer